https://scholars.lib.ntu.edu.tw/handle/123456789/416716
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | YUN-TUNG WANG | en_US |
dc.contributor.author | SZU-HUA PAN | en_US |
dc.contributor.author | CHEN-FENG TSAI | en_US |
dc.contributor.author | TING-CHUN KUO | en_US |
dc.contributor.author | Hsu Y.-L. | en_US |
dc.contributor.author | Yen H.-Y. | en_US |
dc.contributor.author | Choong W.-K. | en_US |
dc.contributor.author | Wu H.-Y. | en_US |
dc.contributor.author | Liao Y.-C. | en_US |
dc.contributor.author | Hong T.-M. | en_US |
dc.contributor.author | Sung T.-Y. | en_US |
dc.contributor.author | PAN-CHYR YANG | en_US |
dc.contributor.author | Chen Y.-J. | en_US |
dc.creator | Chen, Y.-J.;PAN-CHYR YANG;Sung, T.-Y.;Hong, T.-M.;Liao, Y.-C.;Hsin-Yi Wu;Choong, W.-K.;Yen, H.-Y.;Hsu, Y.-L.;TING-CHUN KUO;CHEN-FENG TSAI;SZU-HUA PAN;YUN-TUNG WANG | - |
dc.date.accessioned | 2019-08-27T07:43:02Z | - |
dc.date.available | 2019-08-27T07:43:02Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 2045-2322 | - |
dc.identifier.uri | http://www.scopus.com/inward/record.url?eid=2-s2.0-85015330491&partnerID=MN8TOARS | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/416716 | - |
dc.description.abstract | © 2017 The Author(s). Although EGFR tyrosine kinase inhibitors (TKIs) have demonstrated good efficacy in non-small-cell lung cancer (NSCLC) patients harboring EGFR mutations, most patients develop intrinsic and acquired resistance. We quantitatively profiled the phosphoproteome and proteome of drug-sensitive and drug-resistant NSCLC cells under gefitinib treatment. The construction of a dose-dependent responsive kinase-substrate network of 1548 phosphoproteins and 3834 proteins revealed CK2-centric modules as the dominant core network for the potential gefitinib resistance-associated proteins. CK2 knockdown decreased cell survival in gefitinib-resistant NSCLCs. Using motif analysis to identify the CK2 core sub-network, we verified that elevated phosphorylation level of a CK2 substrate, HMGA1 was a critical node contributing to EGFR-TKI resistance in NSCLC cell. Both HMGA1 knockdown or mutation of the CK2 phosphorylation site, S102, of HMGA1 reinforced the efficacy of gefitinib in resistant NSCLC cells through reactivation of the downstream signaling of EGFR. Our results delineate the TKI resistance-associated kinase-substrate network, suggesting a potential therapeutic strategy for overcoming TKI-induced resistance in NSCLC. | en_US |
dc.language.iso | en | en_US |
dc.publisher | NATURE PUBLISHING GROUP | en_US |
dc.relation.ispartof | Scientific Reports | en_US |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | antineoplastic agent; epidermal growth factor receptor; gefitinib; high mobility group A1a protein; protein kinase inhibitor; quinazoline derivative; apoptosis; drug resistance; human; lung tumor; metabolism; non small cell lung cancer; phosphorylation; protein analysis; proteomics; tumor cell line; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; HMGA1a Protein; Humans; Lung Neoplasms; Phosphorylation; Protein Interaction Maps; Protein Kinase Inhibitors; Proteomics; Quinazolines; Receptor, Epidermal Growth Factor | - |
dc.title | Phosphoproteomics Reveals HMGA1, a CK2 Substrate, as a Drug-Resistant Target in Non-Small Cell Lung Cancer | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1038/srep44021 | - |
dc.identifier.doi | 60947656 | - |
dc.identifier.pmid | 28290473 | - |
dc.identifier.scopus | 2-s2.0-85015330491 | - |
dc.identifier.isi | WOS:000396216500001 | - |
dc.identifier.url | http://www.scopus.com/inward/record.url?eid=2-s2.0-85015330491&partnerID=MN8TOARS | - |
dc.relation.journalvolume | 7 | en_US |
dc.relation.journalissue | 1 | en_US |
dc.identifier.external | 60947656 | - |
item.openairetype | journal article | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Medical Genomics and Proteomics | - |
crisitem.author.dept | Chinese Literature | - |
crisitem.author.dept | Surgery | - |
crisitem.author.dept | Traumatology-NTUH | - |
crisitem.author.dept | Surgery-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.dept | Clinical Pharmacy | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Biomedical Electronics and Bioinformatics | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.orcid | 0000-0001-6304-7744 | - |
crisitem.author.orcid | 0000-0002-0138-0434 | - |
crisitem.author.orcid | 0000-0002-7531-1861 | - |
crisitem.author.orcid | 0000-0003-1960-1423 | - |
crisitem.author.orcid | 0000-0001-6330-6048 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Liberal Arts | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Electrical Engineering and Computer Science | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 基因體暨蛋白體醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。